BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

BMRN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutBioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.Show more

Revenue $2.85B +18.0%
EBITDA $581M +100.1%
Net Income $427M +154.6%
EPS (Diluted) 2.21 +151.1%
Gross Margin 79.67% +2.1%
EBITDA Margin 20.35% +69.6%
Operating Margin 16.97% +120.9%
Net Margin 14.96% +115.8%
ROE 8.05% +129.3%
ROIC 6.82% +151.0%
Debt/Equity 0.11 -48.1%
Interest Coverage 38.23 +256.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 16.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.9%
✓Healthy 5Y average net margin of 14.2%

✗Weaknesses

✗Weak 3Y average ROE of 4.9%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y14.31%

5Y10.86%

3Y15.62%

TTM12.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM61.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM59.28%

ROCE

10Y Avg-2.2%

5Y Avg2.33%

3Y Avg4.72%

Latest8.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	889.89M	1.12B	1.31B	1.49B	1.7B	1.86B	1.85B	2.1B	2.42B	2.85B
Revenue Growth %	0.19%	0.26%	0.18%	0.14%	0.14%	0.09%	-0.01%	0.14%	0.15%	0.18%
Cost of Goods Sold+	152.01M	209.62M	241.79M	315.26M	359.47M	524.27M	470.51M	503.02M	532.06M	580.24M
COGS % of Revenue	0.17%	0.19%	0.18%	0.21%	0.21%	0.28%	0.25%	0.24%	0.22%	0.2%
Gross Profit+	737.89M	907.23M	1.07B	1.18B	1.34B	1.34B	1.38B	1.59B	1.89B	2.27B
Gross Margin %	0.83%	0.81%	0.82%	0.79%	0.79%	0.72%	0.75%	0.76%	0.78%	0.8%
Gross Profit Growth %	0.18%	0.23%	0.18%	0.1%	0.14%	-0.01%	0.03%	0.16%	0.18%	0.2%
Operating Expenses+	848.59M	1.71B	1.09B	1.3B	1.45B	1.38B	1.46B	1.43B	1.7B	1.79B
OpEx % of Revenue	0.95%	1.53%	0.83%	0.87%	0.85%	0.74%	0.79%	0.68%	0.7%	0.63%
Selling, General & Admin	402.27M	476.59M	554.34M	604.4M	680.9M	737.7M	759.4M	823.2M	892.4M	1.01B
SG&A % of Revenue	0.45%	0.43%	0.42%	0.41%	0.4%	0.4%	0.41%	0.39%	0.37%	0.35%
Research & Development	634.81M	661.9M	610.75M	696.33M	715.01M	628.12M	628.79M	649.61M	746.77M	747.18M
R&D % of Revenue	0.71%	0.59%	0.46%	0.47%	0.42%	0.34%	0.34%	0.31%	0.31%	0.26%
Other Operating Expenses	-188.49M	572.16M	-78.53M	-1.21M	49.13M	13.81M	69.91M	-40.76M	62.22M	33.28M
Operating Income+	-110.7M	-803.43M	-14.7M	-123.52M	-100.46M	-43.44M	-82.34M	160.97M	185.77M	484.21M
Operating Margin %	-0.12%	-0.72%	-0.01%	-0.08%	-0.06%	-0.02%	-0.04%	0.08%	0.08%	0.17%
Operating Income Growth %	-0.19%	-6.26%	0.98%	-7.4%	0.19%	0.57%	-0.9%	2.95%	0.15%	1.61%
EBITDA+	-63.52M	-706.52M	73.16M	-27.85M	4.84M	61.73M	25.7M	262.94M	290.16M	580.64M
EBITDA Margin %	-0.07%	-0.63%	0.06%	-0.02%	0%	0.03%	0.01%	0.13%	0.12%	0.2%
EBITDA Growth %	-0.35%	-10.12%	1.1%	-1.38%	1.17%	11.75%	-0.58%	9.23%	0.1%	1%
D&A (Non-Cash Add-back)	47.19M	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M
EBIT	-119.77M	-794.92M	3.11M	-99.04M	-73.38M	-21.52M	-60.61M	163.39M	202.39M	554.1M
Net Interest Income+	-33.74M	-32.01M	-27.85M	-20.83M	-712K	-12.7M	-4.86M	2.06M	41M	62.15M
Interest Income	4.5M	7.49M	14.85M	22.83M	22.75M	16.61M	10.48M	18.03M	58.34M	74.88M
Interest Expense	38.24M	39.5M	42.71M	43.66M	23.46M	29.31M	15.34M	15.97M	17.34M	12.67M
Other Income/Expense	-44.02M	-27.62M	-21.18M	-19.18M	5.65M	-5.56M	6.99M	-11.4M	2.79M	57.55M
Pretax Income+	-154.72M	-831.05M	-35.88M	-142.71M	-94.81M	-49M	-75.35M	149.58M	188.56M	541.76M
Pretax Margin %	-0.17%	-0.74%	-0.03%	-0.1%	-0.06%	-0.03%	-0.04%	0.07%	0.08%	0.19%
Income Tax+	17.07M	-200.84M	81.17M	-65.49M	-70.96M	-903.03M	-11.27M	8.02M	20.92M	114.9M
Effective Tax Rate %	1.11%	0.76%	3.26%	0.54%	0.25%	-17.43%	0.85%	0.95%	0.89%	0.79%
Net Income+	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M
Net Margin %	-0.19%	-0.56%	-0.09%	-0.05%	-0.01%	0.46%	-0.03%	0.07%	0.07%	0.15%
Net Income Growth %	-0.28%	-2.67%	0.81%	0.34%	0.69%	36.81%	-1.08%	3.21%	0.18%	1.55%
Net Income (Continuing)	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.07	-3.79	-0.67	-0.44	-0.13	4.53	-0.35	0.75	0.88	2.21
EPS Growth %	-0.16%	-2.54%	0.82%	0.34%	0.7%	35.85%	-1.08%	3.14%	0.17%	1.51%
EPS (Basic)	-1.07	-3.80	-0.67	-0.44	-0.13	4.75	-0.35	0.76	0.89	2.25
Diluted Shares Outstanding	160.03M	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.59M	196.71M
Basic Shares Outstanding	160.03M	165.99M	174.43M	177.06M	179.04M	180.8M	182.85M	185.27M	187.83M	190.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.09B	1.42B	2.21B	2.06B	1.94B	2.34B	2.27B	2.75B	2.96B	3.23B
Cash & Short-Term Investments	592.62M	789.68M	1.4B	1.08B	753.81M	1.07B	1.01B	1.29B	1.07B	1.14B
Cash Only	397.04M	408.33M	598.03M	493.98M	437.45M	649.16M	587.28M	724.53M	755.13M	942.84M
Short-Term Investments	195.58M	381.35M	797.94M	590.33M	316.36M	416.23M	426.6M	567.01M	318.68M	194.86M
Accounts Receivable	164.96M	215.28M	261.37M	342.63M	377.4M	448.35M	373.4M	461.32M	633.7M	660.53M
Days Sales Outstanding	67.66	70.36	72.62	83.86	80.84	87.96	73.82	80.33	95.61	84.48
Inventory	271.68M	355.13M	475.77M	530.87M	680.27M	698.55M	776.67M	894.08M	1.11B	1.23B
Days Inventory Outstanding	652.36	618.36	718.23	614.62	690.75	486.33	602.5	648.76	759.54	775.41
Other Current Assets	32.42M	61.71M	74.04M	98.4M	130.66M	129.93M	110.44M	104.52M	141.39M	201.53M
Total Non-Current Assets+	2.64B	2.6B	2.43B	2.37B	2.75B	3.51B	3.73B	3.62B	3.89B	3.76B
Property, Plant & Equipment	704.21M	798.77M	896.7M	948.68M	1.01B	1.03B	1.04B	1.07B	1.07B	1.04B
Fixed Asset Turnover	1.26x	1.40x	1.46x	1.57x	1.69x	1.80x	1.78x	1.95x	2.27x	2.74x
Goodwill	197.04M	197.04M	197.04M	197.04M	197.04M	196.2M	196.2M	196.2M	196.2M	196.2M
Intangible Assets	684M	553.78M	517.51M	491.81M	456.58M	417.27M	388.65M	338.57M	294.7M	255.28M
Long-Term Investments	443.71M	572.71M	385.79M	235.86M	411.98M	285.47M	507.79M	333.83M	611.13M	521.24M
Other Non-Current Assets	390.59M	32.81M	29.85M	36.57M	122.01M	142.24M	152.12M	176.24M	171.54M	251.39M
Total Assets+	3.73B	4.02B	4.63B	4.43B	4.69B	5.85B	6B	6.38B	6.84B	6.99B
Asset Turnover	0.24x	0.28x	0.28x	0.34x	0.36x	0.32x	0.31x	0.33x	0.35x	0.41x
Asset Growth %	0.51%	0.08%	0.15%	-0.04%	0.06%	0.25%	0.03%	0.06%	0.07%	0.02%
Total Current Liabilities+	445.46M	439.31M	816.52M	523.24M	932.5M	492.55M	546.5M	588.88M	1.18B	606.99M
Accounts Payable	179.29M	191.35M	166.62M	207.62M	240.98M	191.43M	199.68M	231.24M	315.51M	235.4M
Days Payables Outstanding	430.52	333.19	251.52	240.37	244.69	133.27	154.9	167.79	216.44	148.08
Short-Term Debt	0	22.48M	360.95M	0	361.88M	0	0	0	493.88M	23.07M
Deferred Revenue (Current)	0	0	0	1000K	1000K	152K	1000K	711K	1000K	1000K
Other Current Liabilities	148.29M	160.57M	208.89M	240.07M	202.91M	182.82M	258.94M	236.1M	234.92M	132.06M
Current Ratio	2.45x	3.24x	2.70x	3.93x	2.08x	4.76x	4.16x	4.67x	2.51x	5.33x
Quick Ratio	1.84x	2.43x	2.12x	2.92x	1.35x	3.34x	2.74x	3.15x	1.57x	3.29x
Cash Conversion Cycle	289.5	355.52	539.33	458.11	526.9	441.02	521.42	561.3	638.71	711.8
Total Non-Current Liabilities+	883.06M	818.11M	1.01B	935.95M	635.15M	1.25B	1.19B	1.18B	713.03M	723.96M
Long-Term Debt	662.29M	660.76M	813.52M	830.42M	486.24M	1.08B	1.08B	1.08B	593.1M	595.14M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	31.26M
Deferred Tax Liabilities	143.53M	0	44.32M	62.07M	0	0	0	0	0	0
Other Non-Current Liabilities	77.25M	157.34M	194.42M	105.53M	148.92M	174.32M	113.53M	100.02M	119.94M	97.57M
Total Liabilities	1.33B	1.26B	1.82B	1.46B	1.57B	1.74B	1.74B	1.77B	1.89B	1.33B
Total Debt+	662.29M	683.24M	1.17B	830.42M	858.82M	1.09B	1.09B	1.09B	1.1B	649.47M
Net Debt	265.25M	274.91M	576.44M	336.44M	421.37M	437.74M	502.26M	368.86M	340.62M	-293.38M
Debt / Equity	0.28x	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x
Debt / EBITDA	-	-	16.05x	-	177.33x	17.61x	42.40x	4.16x	3.78x	1.12x
Net Debt / EBITDA	-	-	7.88x	-	87.01x	7.09x	19.54x	1.40x	1.17x	-0.51x
Interest Coverage	-2.89x	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x
Total Equity+	2.4B	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B
Equity Growth %	0.57%	0.15%	0.02%	0.06%	0.05%	0.32%	0.04%	0.08%	0.08%	0.14%
Book Value per Share	15.00	16.64	16.10	16.74	17.44	21.42	23.33	24.36	25.84	28.76
Total Shareholders' Equity	2.4B	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B
Common Stock	162K	173K	176K	178K	180K	182K	184K	186K	189K	191K
Retained Earnings	-1.02B	-1.52B	-1.64B	-1.69B	-1.72B	-861.61M	-930.76M	-789.2M	-621.55M	-194.69M
Treasury Stock	-13.62M	-14.32M	-14.22M	-13.3M	-9.96M	-9.84M	0	0	0	0
Accumulated OCI	21.03M	12.82M	-22.96M	5.27M	20.16M	-16.14M	14.43M	-3.87M	-28.79M	61.65M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-221.69M	-227.84M	-8.76M	20.21M	48.26M	85.36M	304.54M	175.9M	159.26M	572.84M
Operating CF Margin %	-0.25%	-0.2%	-0.01%	0.01%	0.03%	0.05%	0.16%	0.08%	0.07%	0.2%
Operating CF Growth %	-2.01%	-0.03%	0.96%	3.31%	1.39%	0.77%	2.57%	-0.42%	-0.09%	2.6%
Net Income	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	859.1M	-64.08M	141.56M	167.65M	426.86M
Depreciation & Amortization	47.19M	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M
Stock-Based Compensation	111.53M	134.64M	140.26M	148.82M	0	189.71M	197.26M	0	0	201.57M
Deferred Taxes	-76.83M	-228.05M	44.46M	-68.38M	-82.76M	-888.91M	-15.61M	-52.09M	-44.98M	56.1M
Other Non-Cash Items	-178.11M	559.15M	-70.34M	-29.27M	150.66M	44.71M	12.89M	80.84M	268.75M	8.29M
Working Capital Changes	46.33M	-160.28M	-93.96M	-49.42M	-101.09M	-224.42M	66.03M	-96.38M	-336.54M	-216.4M
Change in Receivables	-16.37M	-51.48M	-25.26M	-54.27M	-37.85M	-59.03M	65.57M	-82.03M	-190.44M	-57.91M
Change in Inventory	-50.99M	-64.51M	-96.89M	-23.75M	-107.55M	-61.15M	-35.06M	-68.26M	-157.06M	-63.53M
Change in Payables	116.1M	-33.89M	24.83M	20.62M	77.09M	-68.71M	15.69M	59.02M	68.85M	-32.24M
Cash from Investing+	-1.18B	-484.05M	-305.46M	264.35M	-31.03M	-53.62M	-366.31M	-20.03M	-111.24M	136.49M
Capital Expenditures	-227.65M	-148.38M	-199.22M	-144.62M	-163.41M	-137.52M	-95.58M	-131.54M	-107.61M	-85.42M
CapEx % of Revenue	0.26%	0.13%	0.15%	0.1%	0.1%	0.07%	0.05%	0.06%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	410M	-698K	-1.75M	-10K	24.19M	89.64M	-24.64M	103.33M	0	-853K
Cash from Financing+	927.91M	727.11M	507.14M	-388.01M	-74.67M	181.12M	-48K	-18.65M	-18.73M	-526.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-23.39M	14.17M	25.46M	-13.05M	-101.2M	27.27M	2.99M	-85.38M	-85.79M	-31.46M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-449.34M	-376.22M	-207.98M	-124.41M	-96.76M	-52.15M	185.31M	54.94M	62.57M	475.42M
FCF Margin %	-0.5%	-0.34%	-0.16%	-0.08%	-0.06%	-0.03%	0.1%	0.03%	0.03%	0.17%
FCF Growth %	-1.34%	0.16%	0.45%	0.4%	0.22%	0.46%	4.55%	-0.7%	0.14%	6.6%
FCF per Share	-2.81	-2.26	-1.19	-0.70	-0.54	-0.27	1.01	0.29	0.33	2.42
FCF Conversion (FCF/Net Income)	1.29x	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x
Interest Paid	9.31M	8.64M	8.54M	11.62M	0	12.18M	10.39M	0	0	10.36M
Taxes Paid	16.08M	95.86M	23.89M	16.68M	0	8.98M	18.15M	0	0	57.27M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-8.75%	-24.39%	-4.2%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%
Return on Invested Capital (ROIC)	-4.19%	-21.12%	-0.34%	-2.77%	-2.2%	-0.81%	-1.33%	2.48%	2.71%	6.82%
Gross Margin	82.92%	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%
Net Margin	-19.31%	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%
Debt / Equity	0.28x	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x
Interest Coverage	-2.89x	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x
FCF Conversion	1.29x	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x
Revenue Growth	18.77%	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	1.78B	2.04B	2.37B	2.81B
Product Growth	-	-	-	-	-	-	-	14.50%	16.19%	18.42%
Royalty And Other	-	-	-	20.86M	43.01M	54.59M	62.78M	54.01M	46.69M	44.47M
Royalty And Other Growth	-	-	-	-	106.20%	26.95%	14.99%	-13.96%	-13.56%	-4.75%
Enzyme Product	-	-	-	-	-	-	-	-	1.72B	-
Enzyme Product Growth	-	-	-	-	-	-	-	-	-	-
Product Four	97.91M	354.06M	-	481.98M	544.35M	-	-	-	-	-
Product Four Growth	-	261.61%	-	-	12.94%	-	-	-	-	-
Product Three	239.34M	296.54M	-	433.58M	463.35M	-	-	-	-	-
Product Three Growth	-	23.90%	-	-	6.87%	-	-	-	-	-
Product Two	303.09M	348.01M	-	345.85M	374.33M	-	-	-	-	-
Product Two Growth	-	14.82%	-	-	8.24%	-	-	-	-	-
Product Seven	-	-	-	12.17M	86.86M	-	-	-	-	-
Product Seven Growth	-	-	-	-	613.52%	-	-	-	-	-
Product Six	-	-	-	39.89M	72M	-	-	-	-	-
Product Six Growth	-	-	-	-	80.49%	-	-	-	-	-
Product Five	16.04M	18.03M	18.89M	21.79M	22.35M	-	-	-	-	-
Product Five Growth	-	12.42%	4.78%	15.34%	2.57%	-	-	-	-	-
Product One	228.15M	93.75M	-	-	-	-	-	-	-	-
Product One Growth	-	-58.91%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	507.54M	588.24M	696.79M	778.44M	912.38M	-	-	-	-
UNITED STATES Growth	-	-	15.90%	18.45%	11.72%	17.21%	-	-	-	-
Europe	178.75M	252.63M	301.49M	436.43M	509.19M	518.47M	-	-	-	-
Europe Growth	-	41.34%	19.34%	44.76%	16.67%	1.82%	-	-	-	-
Rest Of World	124.77M	209.21M	241.48M	172.94M	197.63M	223.75M	-	-	-	-
Rest Of World Growth	-	67.68%	15.42%	-28.38%	14.28%	13.22%	-	-	-	-
Latin America	142.31M	147.47M	182.44M	185.05M	218.79M	205.86M	-	-	-	-
Latin America Growth	-	3.63%	23.71%	1.43%	18.24%	-5.91%	-	-	-	-
U S	444.07M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

BioMarin Pharmaceutical Inc. (BMRN) has a price-to-earnings (P/E) ratio of 24.9x. This is roughly in line with market averages.

Growth & Financials

BioMarin Pharmaceutical Inc. (BMRN) reported $3.09B in revenue for fiscal year 2024. This represents a 601% increase from $441.4M in 2011.

BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 18.0% over the past year. This is strong growth.

Yes, BioMarin Pharmaceutical Inc. (BMRN) is profitable, generating $520.4M in net income for fiscal year 2024 (15.0% net margin).

Dividend & Returns

BioMarin Pharmaceutical Inc. (BMRN) has a return on equity (ROE) of 8.0%. This is below average, suggesting room for improvement.

BioMarin Pharmaceutical Inc. (BMRN) generated $831.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

BioMarin Pharmaceutical Inc. (BMRN) 10-Year Financial Performance & Capital Metrics

BMRN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $2.85B +18.0%
EBITDA $581M +100.1%
Net Income $427M +154.6%
EPS (Diluted) 2.21 +151.1%
Gross Margin 79.67% +2.1%
EBITDA Margin 20.35% +69.6%
Operating Margin 16.97% +120.9%
Net Margin 14.96% +115.8%
ROE 8.05% +129.3%
ROIC 6.82% +151.0%
Debt/Equity 0.11 -48.1%
Interest Coverage 38.23 +256.7%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 16.7% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.9%
✓Healthy 5Y average net margin of 14.2%

✗Weaknesses

✗Weak 3Y average ROE of 4.9%

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y14.31%

5Y10.86%

3Y15.62%

TTM12.39%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM61.47%

EPS CAGR

10Y-

5Y-

3Y-

TTM59.28%

ROCE

10Y Avg-2.2%

5Y Avg2.33%

3Y Avg4.72%

Latest8.04%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	889.89M	1.12B	1.31B	1.49B	1.7B	1.86B	1.85B	2.1B	2.42B	2.85B
Revenue Growth %	0.19%	0.26%	0.18%	0.14%	0.14%	0.09%	-0.01%	0.14%	0.15%	0.18%
Cost of Goods Sold+	152.01M	209.62M	241.79M	315.26M	359.47M	524.27M	470.51M	503.02M	532.06M	580.24M
COGS % of Revenue	0.17%	0.19%	0.18%	0.21%	0.21%	0.28%	0.25%	0.24%	0.22%	0.2%
Gross Profit+	737.89M	907.23M	1.07B	1.18B	1.34B	1.34B	1.38B	1.59B	1.89B	2.27B
Gross Margin %	0.83%	0.81%	0.82%	0.79%	0.79%	0.72%	0.75%	0.76%	0.78%	0.8%
Gross Profit Growth %	0.18%	0.23%	0.18%	0.1%	0.14%	-0.01%	0.03%	0.16%	0.18%	0.2%
Operating Expenses+	848.59M	1.71B	1.09B	1.3B	1.45B	1.38B	1.46B	1.43B	1.7B	1.79B
OpEx % of Revenue	0.95%	1.53%	0.83%	0.87%	0.85%	0.74%	0.79%	0.68%	0.7%	0.63%
Selling, General & Admin	402.27M	476.59M	554.34M	604.4M	680.9M	737.7M	759.4M	823.2M	892.4M	1.01B
SG&A % of Revenue	0.45%	0.43%	0.42%	0.41%	0.4%	0.4%	0.41%	0.39%	0.37%	0.35%
Research & Development	634.81M	661.9M	610.75M	696.33M	715.01M	628.12M	628.79M	649.61M	746.77M	747.18M
R&D % of Revenue	0.71%	0.59%	0.46%	0.47%	0.42%	0.34%	0.34%	0.31%	0.31%	0.26%
Other Operating Expenses	-188.49M	572.16M	-78.53M	-1.21M	49.13M	13.81M	69.91M	-40.76M	62.22M	33.28M
Operating Income+	-110.7M	-803.43M	-14.7M	-123.52M	-100.46M	-43.44M	-82.34M	160.97M	185.77M	484.21M
Operating Margin %	-0.12%	-0.72%	-0.01%	-0.08%	-0.06%	-0.02%	-0.04%	0.08%	0.08%	0.17%
Operating Income Growth %	-0.19%	-6.26%	0.98%	-7.4%	0.19%	0.57%	-0.9%	2.95%	0.15%	1.61%
EBITDA+	-63.52M	-706.52M	73.16M	-27.85M	4.84M	61.73M	25.7M	262.94M	290.16M	580.64M
EBITDA Margin %	-0.07%	-0.63%	0.06%	-0.02%	0%	0.03%	0.01%	0.13%	0.12%	0.2%
EBITDA Growth %	-0.35%	-10.12%	1.1%	-1.38%	1.17%	11.75%	-0.58%	9.23%	0.1%	1%
D&A (Non-Cash Add-back)	47.19M	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M
EBIT	-119.77M	-794.92M	3.11M	-99.04M	-73.38M	-21.52M	-60.61M	163.39M	202.39M	554.1M
Net Interest Income+	-33.74M	-32.01M	-27.85M	-20.83M	-712K	-12.7M	-4.86M	2.06M	41M	62.15M
Interest Income	4.5M	7.49M	14.85M	22.83M	22.75M	16.61M	10.48M	18.03M	58.34M	74.88M
Interest Expense	38.24M	39.5M	42.71M	43.66M	23.46M	29.31M	15.34M	15.97M	17.34M	12.67M
Other Income/Expense	-44.02M	-27.62M	-21.18M	-19.18M	5.65M	-5.56M	6.99M	-11.4M	2.79M	57.55M
Pretax Income+	-154.72M	-831.05M	-35.88M	-142.71M	-94.81M	-49M	-75.35M	149.58M	188.56M	541.76M
Pretax Margin %	-0.17%	-0.74%	-0.03%	-0.1%	-0.06%	-0.03%	-0.04%	0.07%	0.08%	0.19%
Income Tax+	17.07M	-200.84M	81.17M	-65.49M	-70.96M	-903.03M	-11.27M	8.02M	20.92M	114.9M
Effective Tax Rate %	1.11%	0.76%	3.26%	0.54%	0.25%	-17.43%	0.85%	0.95%	0.89%	0.79%
Net Income+	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M
Net Margin %	-0.19%	-0.56%	-0.09%	-0.05%	-0.01%	0.46%	-0.03%	0.07%	0.07%	0.15%
Net Income Growth %	-0.28%	-2.67%	0.81%	0.34%	0.69%	36.81%	-1.08%	3.21%	0.18%	1.55%
Net Income (Continuing)	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	854.03M	-64.08M	141.56M	167.65M	426.86M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.07	-3.79	-0.67	-0.44	-0.13	4.53	-0.35	0.75	0.88	2.21
EPS Growth %	-0.16%	-2.54%	0.82%	0.34%	0.7%	35.85%	-1.08%	3.14%	0.17%	1.51%
EPS (Basic)	-1.07	-3.80	-0.67	-0.44	-0.13	4.75	-0.35	0.76	0.89	2.25
Diluted Shares Outstanding	160.03M	166.22M	174.43M	177.27M	179.04M	191.68M	182.85M	188.96M	191.59M	196.71M
Basic Shares Outstanding	160.03M	165.99M	174.43M	177.06M	179.04M	180.8M	182.85M	185.27M	187.83M	190.03M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.09B	1.42B	2.21B	2.06B	1.94B	2.34B	2.27B	2.75B	2.96B	3.23B
Cash & Short-Term Investments	592.62M	789.68M	1.4B	1.08B	753.81M	1.07B	1.01B	1.29B	1.07B	1.14B
Cash Only	397.04M	408.33M	598.03M	493.98M	437.45M	649.16M	587.28M	724.53M	755.13M	942.84M
Short-Term Investments	195.58M	381.35M	797.94M	590.33M	316.36M	416.23M	426.6M	567.01M	318.68M	194.86M
Accounts Receivable	164.96M	215.28M	261.37M	342.63M	377.4M	448.35M	373.4M	461.32M	633.7M	660.53M
Days Sales Outstanding	67.66	70.36	72.62	83.86	80.84	87.96	73.82	80.33	95.61	84.48
Inventory	271.68M	355.13M	475.77M	530.87M	680.27M	698.55M	776.67M	894.08M	1.11B	1.23B
Days Inventory Outstanding	652.36	618.36	718.23	614.62	690.75	486.33	602.5	648.76	759.54	775.41
Other Current Assets	32.42M	61.71M	74.04M	98.4M	130.66M	129.93M	110.44M	104.52M	141.39M	201.53M
Total Non-Current Assets+	2.64B	2.6B	2.43B	2.37B	2.75B	3.51B	3.73B	3.62B	3.89B	3.76B
Property, Plant & Equipment	704.21M	798.77M	896.7M	948.68M	1.01B	1.03B	1.04B	1.07B	1.07B	1.04B
Fixed Asset Turnover	1.26x	1.40x	1.46x	1.57x	1.69x	1.80x	1.78x	1.95x	2.27x	2.74x
Goodwill	197.04M	197.04M	197.04M	197.04M	197.04M	196.2M	196.2M	196.2M	196.2M	196.2M
Intangible Assets	684M	553.78M	517.51M	491.81M	456.58M	417.27M	388.65M	338.57M	294.7M	255.28M
Long-Term Investments	443.71M	572.71M	385.79M	235.86M	411.98M	285.47M	507.79M	333.83M	611.13M	521.24M
Other Non-Current Assets	390.59M	32.81M	29.85M	36.57M	122.01M	142.24M	152.12M	176.24M	171.54M	251.39M
Total Assets+	3.73B	4.02B	4.63B	4.43B	4.69B	5.85B	6B	6.38B	6.84B	6.99B
Asset Turnover	0.24x	0.28x	0.28x	0.34x	0.36x	0.32x	0.31x	0.33x	0.35x	0.41x
Asset Growth %	0.51%	0.08%	0.15%	-0.04%	0.06%	0.25%	0.03%	0.06%	0.07%	0.02%
Total Current Liabilities+	445.46M	439.31M	816.52M	523.24M	932.5M	492.55M	546.5M	588.88M	1.18B	606.99M
Accounts Payable	179.29M	191.35M	166.62M	207.62M	240.98M	191.43M	199.68M	231.24M	315.51M	235.4M
Days Payables Outstanding	430.52	333.19	251.52	240.37	244.69	133.27	154.9	167.79	216.44	148.08
Short-Term Debt	0	22.48M	360.95M	0	361.88M	0	0	0	493.88M	23.07M
Deferred Revenue (Current)	0	0	0	1000K	1000K	152K	1000K	711K	1000K	1000K
Other Current Liabilities	148.29M	160.57M	208.89M	240.07M	202.91M	182.82M	258.94M	236.1M	234.92M	132.06M
Current Ratio	2.45x	3.24x	2.70x	3.93x	2.08x	4.76x	4.16x	4.67x	2.51x	5.33x
Quick Ratio	1.84x	2.43x	2.12x	2.92x	1.35x	3.34x	2.74x	3.15x	1.57x	3.29x
Cash Conversion Cycle	289.5	355.52	539.33	458.11	526.9	441.02	521.42	561.3	638.71	711.8
Total Non-Current Liabilities+	883.06M	818.11M	1.01B	935.95M	635.15M	1.25B	1.19B	1.18B	713.03M	723.96M
Long-Term Debt	662.29M	660.76M	813.52M	830.42M	486.24M	1.08B	1.08B	1.08B	593.1M	595.14M
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	31.26M
Deferred Tax Liabilities	143.53M	0	44.32M	62.07M	0	0	0	0	0	0
Other Non-Current Liabilities	77.25M	157.34M	194.42M	105.53M	148.92M	174.32M	113.53M	100.02M	119.94M	97.57M
Total Liabilities	1.33B	1.26B	1.82B	1.46B	1.57B	1.74B	1.74B	1.77B	1.89B	1.33B
Total Debt+	662.29M	683.24M	1.17B	830.42M	858.82M	1.09B	1.09B	1.09B	1.1B	649.47M
Net Debt	265.25M	274.91M	576.44M	336.44M	421.37M	437.74M	502.26M	368.86M	340.62M	-293.38M
Debt / Equity	0.28x	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x
Debt / EBITDA	-	-	16.05x	-	177.33x	17.61x	42.40x	4.16x	3.78x	1.12x
Net Debt / EBITDA	-	-	7.88x	-	87.01x	7.09x	19.54x	1.40x	1.17x	-0.51x
Interest Coverage	-2.89x	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x
Total Equity+	2.4B	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B
Equity Growth %	0.57%	0.15%	0.02%	0.06%	0.05%	0.32%	0.04%	0.08%	0.08%	0.14%
Book Value per Share	15.00	16.64	16.10	16.74	17.44	21.42	23.33	24.36	25.84	28.76
Total Shareholders' Equity	2.4B	2.77B	2.81B	2.97B	3.12B	4.11B	4.27B	4.6B	4.95B	5.66B
Common Stock	162K	173K	176K	178K	180K	182K	184K	186K	189K	191K
Retained Earnings	-1.02B	-1.52B	-1.64B	-1.69B	-1.72B	-861.61M	-930.76M	-789.2M	-621.55M	-194.69M
Treasury Stock	-13.62M	-14.32M	-14.22M	-13.3M	-9.96M	-9.84M	0	0	0	0
Accumulated OCI	21.03M	12.82M	-22.96M	5.27M	20.16M	-16.14M	14.43M	-3.87M	-28.79M	61.65M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-221.69M	-227.84M	-8.76M	20.21M	48.26M	85.36M	304.54M	175.9M	159.26M	572.84M
Operating CF Margin %	-0.25%	-0.2%	-0.01%	0.01%	0.03%	0.05%	0.16%	0.08%	0.07%	0.2%
Operating CF Growth %	-2.01%	-0.03%	0.96%	3.31%	1.39%	0.77%	2.57%	-0.42%	-0.09%	2.6%
Net Income	-171.8M	-630.21M	-117.04M	-77.21M	-23.85M	859.1M	-64.08M	141.56M	167.65M	426.86M
Depreciation & Amortization	47.19M	96.91M	87.86M	95.67M	105.3M	105.17M	108.04M	101.97M	104.39M	96.43M
Stock-Based Compensation	111.53M	134.64M	140.26M	148.82M	0	189.71M	197.26M	0	0	201.57M
Deferred Taxes	-76.83M	-228.05M	44.46M	-68.38M	-82.76M	-888.91M	-15.61M	-52.09M	-44.98M	56.1M
Other Non-Cash Items	-178.11M	559.15M	-70.34M	-29.27M	150.66M	44.71M	12.89M	80.84M	268.75M	8.29M
Working Capital Changes	46.33M	-160.28M	-93.96M	-49.42M	-101.09M	-224.42M	66.03M	-96.38M	-336.54M	-216.4M
Change in Receivables	-16.37M	-51.48M	-25.26M	-54.27M	-37.85M	-59.03M	65.57M	-82.03M	-190.44M	-57.91M
Change in Inventory	-50.99M	-64.51M	-96.89M	-23.75M	-107.55M	-61.15M	-35.06M	-68.26M	-157.06M	-63.53M
Change in Payables	116.1M	-33.89M	24.83M	20.62M	77.09M	-68.71M	15.69M	59.02M	68.85M	-32.24M
Cash from Investing+	-1.18B	-484.05M	-305.46M	264.35M	-31.03M	-53.62M	-366.31M	-20.03M	-111.24M	136.49M
Capital Expenditures	-227.65M	-148.38M	-199.22M	-144.62M	-163.41M	-137.52M	-95.58M	-131.54M	-107.61M	-85.42M
CapEx % of Revenue	0.26%	0.13%	0.15%	0.1%	0.1%	0.07%	0.05%	0.06%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	410M	-698K	-1.75M	-10K	24.19M	89.64M	-24.64M	103.33M	0	-853K
Cash from Financing+	927.91M	727.11M	507.14M	-388.01M	-74.67M	181.12M	-48K	-18.65M	-18.73M	-526.45M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-23.39M	14.17M	25.46M	-13.05M	-101.2M	27.27M	2.99M	-85.38M	-85.79M	-31.46M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-449.34M	-376.22M	-207.98M	-124.41M	-96.76M	-52.15M	185.31M	54.94M	62.57M	475.42M
FCF Margin %	-0.5%	-0.34%	-0.16%	-0.08%	-0.06%	-0.03%	0.1%	0.03%	0.03%	0.17%
FCF Growth %	-1.34%	0.16%	0.45%	0.4%	0.22%	0.46%	4.55%	-0.7%	0.14%	6.6%
FCF per Share	-2.81	-2.26	-1.19	-0.70	-0.54	-0.27	1.01	0.29	0.33	2.42
FCF Conversion (FCF/Net Income)	1.29x	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x
Interest Paid	9.31M	8.64M	8.54M	11.62M	0	12.18M	10.39M	0	0	10.36M
Taxes Paid	16.08M	95.86M	23.89M	16.68M	0	8.98M	18.15M	0	0	57.27M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-8.75%	-24.39%	-4.2%	-2.67%	-0.78%	23.63%	-1.53%	3.19%	3.51%	8.05%
Return on Invested Capital (ROIC)	-4.19%	-21.12%	-0.34%	-2.77%	-2.2%	-0.81%	-1.33%	2.48%	2.71%	6.82%
Gross Margin	82.92%	81.23%	81.59%	78.86%	78.91%	71.82%	74.52%	76%	78.01%	79.67%
Net Margin	-19.31%	-56.43%	-8.91%	-5.18%	-1.4%	45.9%	-3.47%	6.75%	6.93%	14.96%
Debt / Equity	0.28x	0.25x	0.42x	0.28x	0.28x	0.26x	0.26x	0.24x	0.22x	0.11x
Interest Coverage	-2.89x	-20.34x	-0.34x	-2.83x	-4.28x	-1.48x	-5.37x	10.08x	10.72x	38.23x
FCF Conversion	1.29x	0.36x	0.07x	-0.26x	-2.02x	0.10x	-4.75x	1.24x	0.95x	1.34x
Revenue Growth	18.77%	25.5%	17.62%	13.52%	14.27%	9.18%	-0.76%	13.53%	15.42%	17.97%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Product	-	-	-	-	-	-	1.78B	2.04B	2.37B	2.81B
Product Growth	-	-	-	-	-	-	-	14.50%	16.19%	18.42%
Royalty And Other	-	-	-	20.86M	43.01M	54.59M	62.78M	54.01M	46.69M	44.47M
Royalty And Other Growth	-	-	-	-	106.20%	26.95%	14.99%	-13.96%	-13.56%	-4.75%
Enzyme Product	-	-	-	-	-	-	-	-	1.72B	-
Enzyme Product Growth	-	-	-	-	-	-	-	-	-	-
Product Four	97.91M	354.06M	-	481.98M	544.35M	-	-	-	-	-
Product Four Growth	-	261.61%	-	-	12.94%	-	-	-	-	-
Product Three	239.34M	296.54M	-	433.58M	463.35M	-	-	-	-	-
Product Three Growth	-	23.90%	-	-	6.87%	-	-	-	-	-
Product Two	303.09M	348.01M	-	345.85M	374.33M	-	-	-	-	-
Product Two Growth	-	14.82%	-	-	8.24%	-	-	-	-	-
Product Seven	-	-	-	12.17M	86.86M	-	-	-	-	-
Product Seven Growth	-	-	-	-	613.52%	-	-	-	-	-
Product Six	-	-	-	39.89M	72M	-	-	-	-	-
Product Six Growth	-	-	-	-	80.49%	-	-	-	-	-
Product Five	16.04M	18.03M	18.89M	21.79M	22.35M	-	-	-	-	-
Product Five Growth	-	12.42%	4.78%	15.34%	2.57%	-	-	-	-	-
Product One	228.15M	93.75M	-	-	-	-	-	-	-	-
Product One Growth	-	-58.91%	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	-	507.54M	588.24M	696.79M	778.44M	912.38M	-	-	-	-
UNITED STATES Growth	-	-	15.90%	18.45%	11.72%	17.21%	-	-	-	-
Europe	178.75M	252.63M	301.49M	436.43M	509.19M	518.47M	-	-	-	-
Europe Growth	-	41.34%	19.34%	44.76%	16.67%	1.82%	-	-	-	-
Rest Of World	124.77M	209.21M	241.48M	172.94M	197.63M	223.75M	-	-	-	-
Rest Of World Growth	-	67.68%	15.42%	-28.38%	14.28%	13.22%	-	-	-	-
Latin America	142.31M	147.47M	182.44M	185.05M	218.79M	205.86M	-	-	-	-
Latin America Growth	-	3.63%	23.71%	1.43%	18.24%	-5.91%	-	-	-	-
U S	444.07M	-	-	-	-	-	-	-	-	-
U S Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

BioMarin Pharmaceutical Inc. (BMRN) has a price-to-earnings (P/E) ratio of 24.9x. This is roughly in line with market averages.

Growth & Financials

BioMarin Pharmaceutical Inc. (BMRN) reported $3.09B in revenue for fiscal year 2024. This represents a 601% increase from $441.4M in 2011.

BioMarin Pharmaceutical Inc. (BMRN) grew revenue by 18.0% over the past year. This is strong growth.

Yes, BioMarin Pharmaceutical Inc. (BMRN) is profitable, generating $520.4M in net income for fiscal year 2024 (15.0% net margin).

Dividend & Returns

BioMarin Pharmaceutical Inc. (BMRN) has a return on equity (ROE) of 8.0%. This is below average, suggesting room for improvement.

BioMarin Pharmaceutical Inc. (BMRN) generated $831.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.